Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients
Open Access
- 9 September 2008
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 21 (10) , 963-971
Abstract
Development of Epstein‐Barr virus (EBV)‐associated post‐transplant lymphoproliferative disease (PTLD) is a serious complication following heart transplantation (HTX). This study investigates EBV DNA load in adult heart transplant recipients, its association with immunosuppression, and its potential as a marker for development of PTLD. EBV DNA load was measured prospectively by quantitative real‐time polymerase chain reaction (PCR) in 172 stable HTX patients. Sixty‐seven patients (39.0% of total) had a positive EBV PCR at initial examination [median 4.9 (range 1.1–16.9) years post‐HTX]. In follow‐up testing of 67 positive patients 6 months later, 36 patients continued to have a positive EBV PCR. Overall incidence of EBV DNA was significantly associated with calcineurin inihibitors, azathioprine medication, and with the absence of mycophenolate mofetil (MMF) treatment. In patients with positive EBV DNA levels at initial examination and negative levels at retesting, cyclosporine A levels were found to be significantly higher at initial examination (148.4 ± 70.2 vs. 119.6 ± 53.5 ng/ml, P < 0.05). Three patients (1.7%, 3/172) were diagnosed with PTLD during the course of the study (mean follow up 4.0 years). EBV DNA viral load determination does not appear to be useful for risk prediction or early diagnosis of PTLD in adults after HTX, but an association of EBV DNA load with qualitative and quantitative immunosuppression is demonstrated.Keywords
This publication has 26 references indexed in Scilit:
- Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant RecipientsTransplantation, 2007
- Case–control study of risk factors for the development of post‐transplant lymphoproliferative disease in a pediatric heart transplant cohort*Pediatric Transplantation, 2006
- Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipientsClinical Transplantation, 2006
- Management of patients with post-transplant lymphoproliferative disorder: the role of rituximabTransplant International, 2006
- A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative DisorderTransplantation, 2006
- Monitoring of Epstein–Barr Viral Load in Pediatric Heart and Lung Transplant Recipients by Real-time Polymerase Chain ReactionThe Journal of Heart and Lung Transplantation, 2005
- Impact of Pre-Operative Diabetes Mellitus Upon Early and Late Survival After Heart Transplantation: A Possible Era EffectThe Journal of Heart and Lung Transplantation, 2005
- Effectivity of a T-Cell-Adapted Induction Therapy With Anti-Thymocyte Globulin (Sangstat)The Journal of Heart and Lung Transplantation, 2005
- Chronic high Epstein-Barr virus load carrier state and risk for late onset PTLD/malignant lymphomaThe Journal of Heart and Lung Transplantation, 2005
- COINCIDENCE OF EPSTEIN-BARR VIRUS REACTIVATION, CYTOMEGALOVIRUS INFECTION, AND REJECTION EPISODES IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1995